Quick Answer
Akebia Therapeutics, Inc. reported Stockholders Equity of $32.61 million for fiscal year 2025.
Akebia Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $32.61M | +166.3% |
| 2024 | -$49.19M | -60.8% |
| 2023 | -$30.58M | -684.8% |
| 2022 | $5.23M | -92.9% |
| 2021 | $74.01M | -70.1% |
| 2020 | $247.62M | -37.3% |
| 2019 | $394.76M | -37.9% |
| 2018 | $635.93M | +418.8% |
| 2017 | $122.57M | +79.9% |
| 2016 | $68.12M | -48.0% |
| 2015 | $131.00M | +25.9% |
| 2014 | $104.08M | +181.9% |
| 2013 | -$127.07M | -113.3% |
| 2012 | -$59.59M | -23.6% |
| 2011 | -$48.19M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $41.59M | +182.5% | +42.3% |
| June 30, 2025 | $29.22M | +186.6% | +18.9% |
| March 31, 2025 | $24.58M | +190.2% | +150.0% |
| December 31, 2024 | -$49.19M | -60.8% | +2.4% |
| September 30, 2024 | -$50.40M | -27.9% | -49.3% |
| June 30, 2024 | -$33.75M | -25.9% | -23.8% |
| March 31, 2024 | -$27.26M | -42.5% | +10.9% |
| December 31, 2023 | -$30.58M | -684.8% | +22.4% |
- Akebia Therapeutics, Inc. showed an increase of +166.3% in Stockholders Equity compared to the prior fiscal year.
- Over the 2011–2025 period, Akebia Therapeutics, Inc.’s stockholders equity has grown by 167.7% (from -$48.19 million to $32.61 million).
- The most recent figure is from Akebia Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: